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This Month in the Journal
With the advent of very-high-throughput genotyping
techniques, the first genomewide association studies are
under way. However, the best approach to the design of
these studies is still under debate. This month in the
Journal, Duncan Thomas, Robert Haile, and David
Duggan summarize recent discussions that occurred at
a workshop on this topic. Several aspects of genomewide
association studies are covered, including marker selec-
tion, study power, statistical approaches to the data, and
the use of multistage sampling designs. Although a full
understanding of this approach awaits the completion
of more studies, the participants in the workshop were
optimistic that the challenges of genomewide association
studies are surmountable, provided there is appropriate
planning and use of resources.
Chromosome 10q26 and Age-Related Maculopathy,
by Jakobsdottir et al. (p. 389)
Multiple recent reports of the association of complement
factor H with age-related maculopathy (ARM) have in-
dicated that the CFH gene plays an important role in
genetic predisposition to this disorder, which is the lead-
ing cause of central blindness in the elderly. Although
the CFH-containing region on chromosome 1 has been
pulled out in multiple linkage studies of ARM, chromo-
some 10q26 has also been strongly implicated. Jakobs-
dottir et al. focused on these two regions in a linkage
and association study of ARM. They found that var-
iation in CFH accounts for the linkage signal to chro-
mosome 1, although Y402H, which is believed to be the
major determinant of ARM in this gene, may not be the
only important variant. The association to chromosome
10q26 proved more difficult to tease apart. Three tightly
linked genes—PLEKHA1, LOC387715, and PRSS11—
and a second locus containing two genes—GRK5 and
RGS10—both were implicated in the analyses. Taking
their data in total, Jakobsdottir et al. feel that the
PLEKHA1/LOC387715 locus is most likely to be in-
volved in ARM and that it confers an odds ratio for
ARM similar to that of CFH. Because LOC387715
is known to be expressed only in placenta, whereas
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PLEKHA1 is expressed in retina, PLEKHA1 is the most
likely candidate gene. Its function as an activator of lym-
phocytes fits with the proposed role of aberrant immune
responses in ARM.
Duplication of the MECP2 Region in XLMR, by Van
Esch et al. (p. 442)
Loss of function of MECP2 causes Rett syndrome, a dis-
order in which intellectual, motor, and communica-
tion skills are adversely affected and seizures are often
present. Van Esch et al. now find that duplications of
MECP2 and the resultant overexpression of this gene
might also contribute to a Rett-like phenotype. Their
work began with a family with six affected males who
had delays in psychomotor development, seizures, ab-
sence of speech, microcephaly, increased muscle tone and
reflexes, and recurrent respiratory infections. Previous
linkage analysis had assigned the disease locus to Xq28-
Xqter, a region that contains MECP2. However, no mu-
tations were found. Now, Van Esch et al. use an X-
chromosome array to look for alterations in gene dosage
in this family and report a duplication that includes
MECP2. When the authors tested 17 additional indi-
viduals with a similar phenotype, they found three ad-
ditional duplications that were associated with a twofold
increase in MECP2 expression. The minimal region of
overlap of these duplications extends from L1CAM to
MECP2, and these are the only two genes in the dupli-
cation known to be associated with CNS development
and function. The duplications are also found in unaf-
fected carrier females, but these women exhibit extreme
skewing of X inactivation. Although the role of other
genes in the duplication cannot be ruled out, similarities
with the phenotype of mice overexpressing Mecp2 and
the lack of resemblance to phenotypes associated with
L1CAM mutations led the authors argue that the phe-
notype is due largely to overexpression of MECP2. In
support of this argument is the recent work by Meins
et al. (J Med Genet 42:e12), who reported a duplication
in this region that was associated with a similar phe-
notype. This duplication did not include L1CAM, which
leaves MECP2 as the only mental retardation (MR)–
related gene in the overlapping duplicated region. It
therefore appears as though tight regulation of MECP2
expression is crucial for proper development. Not only
does loss of MECP2 function cause Rett syndrome, but
overexpression of MECP2 also appears to cause a severe
MR syndrome.
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MS Linkage Screen, by the International Multiple
Sclerosis Genetics Consortium (p. 454)
Several genome scans for multiple sclerosis (MS) have
been performed, and the only region consistently im-
plicated in this disorder has been the major histocom-
patibility complex (MHC) region on chromosome 6p21.
Members of the International Multiple Sclerosis Genet-
ics Consortium (IMSGC) felt that the low information
extraction and genotyping success rates in these studies
were not optimal, so they did a pilot study showing that
use of SNP-based mapping sets could greatly improve
these parameters and thus the power of studies using
the same samples. Encouraged by this result, the IMSGC
has now rescreened available MS-affected families of
Northern European descent with the Illumina BeadArray
linkage mapping panel. They genotyped 14,500 SNPs
in 730 families and were able to achieve an error rate
of only 0.002% and a level of information extraction
nearly twice that of a recent meta-analysis for MS. In a
nonparametric linkage analysis, they achieved a whop-
ping multipoint score of 11.66 for the MHC region,
further cementing the role of the MHC in MS. This score
is much higher than has been reported in previous stud-
ies, thereby illustrating the increase in power that is
achieved through use of the SNP-based strategy. In con-
trast to previous proposals that there may be more than
one MS risk locus within the MHC, the data from this
study suggest that the MHC-based risk can be attributed
solely to the DRB1*1501 haplotype. When they looked
beyond the MHC, they also found suggestive linkage to
chromosomes 17q23 and 5q33, whereas an ordered-
subset analysis (OSA) suggested that a locus on chro-
mosome 19p13 acts independent of MHC to confer risk
of MS. The authors stress that there were no loci outside
the MHC region that had sibling recurrence ratios 11.2,
so future studies of MS candidate genes must be very
powerful to be successful.
Genetics of Cognition in Schizophrenia, by Hallmayer
et al. (p. 468)
Schizophrenia is a complex disease believed to be a con-
glomerate of several disorders. This heterogeneity not
only hinders clinical diagnoses but also presents a sig-
nificant obstacle in the quest for susceptibility genes. The
work of Hallmayer et al. highlights the benefits of an-
alyzing a subset of phenotypes within the schizophrenia
landscape. By focusing on specific cognitive, behavioral,
and personality traits of their subjects, the group is able
to identify a distinct subtype of the disease that is char-
acterized by neurocognitive deficit (CD). This classi-
fication accounts for 30%–50% of the families studied
and provides enough data to reliably link the subtype
to 6p24, a locus previously identified as a potential
schizophrenia hotspot. This locus was identified after
OSA was done on data from a whole-genome scan. Al-
though the LOD scores calculated from the genome scan
are not compelling, OSA reveals that the probands with
CD have a much higher LOD score at 6p24 than does
the overall sample. Of note, when the two groups were
then separated for linkage analysis of the region, the CD
LOD score increased to 3.32, whereas that of the re-
maining families was calculated to be 2.12. Further, it
is reported that, although a battery of tests was used
during the reported study, similar conclusions would
have been made if only four select parameters had been
analyzed. It is hoped that the availability of such an
abridged neurocognitive testing scheme will lead to eas-
ier phenotype classification and the identification of
more homogeneous subtypes of schizophrenia, which
will facilitate genetic analysis.
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